Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2011-01-19 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science annonce la présentation à l’ASCO des données de suivi à 4 ans dans l’étude clinique de phase 2 du masitinib dans le traitement du GIST en première ligne
Regulatory Filings Classification · 95% confidence The document is a press release from AB Science announcing the presentation of 4-year follow-up data from a Phase 2 clinical trial of masitinib for GIST at the ASCO Gastrointestinal Cancers Symposium 2011. It presents key efficacy data (PFS and OS) in comparison to Imatinib and discusses ongoing Phase 3 trials. This type of announcement, detailing clinical trial results and strategic updates, is characteristic of an Earnings Release (ER) if it were focused on financial performance, or an Investor Presentation (IP) if it were a slide deck. However, since it is a formal press release announcing specific clinical data and strategic development progress, it most closely aligns with an Investor Presentation (IP) which often includes detailed scientific/clinical updates intended for investors, or potentially an Earnings Release (ER) if the company typically bundles such news with financial reporting. Given the detailed scientific data tables and discussion of trial phases, 'Investor Presentation' (IP) is a strong fit, as these releases often serve as the primary communication vehicle for detailed clinical milestones to the investment community, even if not formatted as a traditional slide deck. It is not a full financial report (10-K or IR), nor is it a transcript (CT). It is a specific announcement of results, making ER or IP the best candidates. Since it focuses heavily on clinical trial data presentation rather than just quarterly financial highlights, IP is slightly more appropriate than ER, although ER is also plausible for clinical updates. Given the context of presenting data at a major conference, IP is selected.
2011-01-19 French
AB Science announces presentation at ASCO of its 4-year follow-up phase 2 data of masitinib in first line treatment of GIST
Regulatory Filings Classification · 95% confidence The document is an announcement from AB Science detailing the presentation of clinical trial data (Phase 2 follow-up data for masitinib in GIST) at the ASCO Gastrointestinal Cancers Symposium. It contains key financial/clinical results, comparative tables, quotes from the CEO, and details about the ongoing Phase 3 study. This structure—announcing key results and providing context/outlook—is characteristic of an Earnings Release (ER) or a general Investor Presentation (IP). Since it focuses on announcing specific clinical data results rather than a comprehensive quarterly financial review (IR) or a formal presentation deck (IP), and it is a press release format, it aligns best with an Earnings Release (ER) which often includes key operational/clinical highlights for investors. It is not a formal regulatory report like a 10-K or IR, nor is it a simple announcement of a report publication (RPA).
2011-01-19 English
AB Science : autorisation d'initier une phase 2 dans le cancer de l’estomac, portant à 11 le nombre d'indications du programme de développement clinique du masitinib dans les tumeurs solides
Regulatory Filings Classification · 95% confidence The document is dated January 17, 2011, and is an announcement from AB Science regarding receiving authorization from AFSSAPS to initiate a Phase 2 study for masitinib in stomach cancer. The text details the company's entire clinical development program for masitinib across 11 solid tumor indications, including specific details about ongoing Phase 2 and Phase 3 trials (GIST, pancreatic cancer, melanoma, lung cancer, etc.). This content—a detailed update on clinical trial progress, scientific rationale, and future plans—is characteristic of an Investor Presentation (IP) or a comprehensive Management Discussion and Analysis (MDA). Since it provides detailed strategic and operational updates on drug development rather than just preliminary financial highlights (ER) or a formal annual/interim report (10-K/IR), 'Investor Presentation' (IP) is the most fitting category for this type of detailed, forward-looking corporate/clinical update aimed at investors. The length (over 21,000 characters) confirms it is a substantial document, not a brief announcement (RPA/RNS).
2011-01-17 French
AB Science: authorization to initiate phase 2 in stomach cancer with masitinib - Masitinib clinical development program in solid tumors now accounts for 11 indications
Regulatory Filings Classification · 95% confidence The document is a press release dated January 17th, 2011, announcing that AB Science has received authorization from Afssaps to initiate a Phase 2 clinical study for masitinib in stomach cancer. The text details the company's entire clinical development program for masitinib across eleven indications, including specific characteristics of Phase 2 and Phase 3 trials (e.g., primary endpoints, randomization groups, combination therapies). This content—a detailed update on ongoing and planned clinical trials, scientific rationale, and company background—is characteristic of an Investor Presentation (IP) or a detailed corporate update, rather than a brief Earnings Release (ER) or a formal regulatory filing like a 10-K or IR. Since it is a detailed presentation of strategy and pipeline progress aimed at investors, Investor Presentation (IP) is the most appropriate classification.
2011-01-17 English
AB Science : recrutement du premier patient dans l’étude de phase 2 dans le mélanome métastatique
Investor Presentation Classification · 95% confidence The document is a press release dated January 13, 2011, announcing that AB Science has recruited the first patient in a Phase 2 study evaluating masitinib for metastatic melanoma. It details the study design, scientific rationale, and provides background information on the drug and the company. This type of announcement, detailing clinical trial progress and scientific updates, is characteristic of an Investor Presentation (IP) or a general corporate update. Since it is a detailed announcement about ongoing clinical development and strategy, 'Investor Presentation' (IP) is the most fitting category, as it serves to inform investors about key operational milestones and scientific progress, which often overlaps with the content of an IP, even if formatted as a press release. It is not a formal regulatory filing like 10-K or IR, nor is it a short announcement of a report (RPA/RNS).
2011-01-13 French
AB Science: recruitment of first patient in phase 2 study in metastatic melanoma
Investor Presentation Classification · 95% confidence The document is a press release dated January 13th, 2011, announcing the recruitment of the first patient in a Phase 2 clinical study for masitinib in metastatic melanoma. It details the study design, scientific rationale, and background information on the drug and the company (AB Science). This type of announcement, detailing ongoing clinical trial progress and scientific updates, is characteristic of an Investor Presentation (IP) or a general press release related to R&D activities. Since it is a detailed announcement about a specific development program and strategy, 'Investor Presentation' (IP) is the most fitting category, as these often contain detailed scientific and strategic updates intended for investors, even if formatted as a press release. It is not a formal regulatory filing like 10-K or IR, nor is it a short announcement of a report (RPA/RNS).
2011-01-13 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.